Table 1.

Patient number, tumor site, disease stage, and prescription dose

Patient	Tumor histology and site	Disease stage	Prescription dose and fractionation scheme
1	NSCLC left lung	T3N2M1	60 Gy, 20 fractions
2	NSCLC RLL (post surgery)	T2M2N0	50.4 Gy, 28 fractions
3	Adenocarcinoma distal esophagus	T3N1M0	50.4 Gy, 28 fractions
4	NSCLC RUL	T1N0M0	70 Gy, 35 fractions
5	NSCLC LUL	T1N2M0	63 Gy, 35 fractions
6	NSCLC LUL	T1N0M0	50 Gy, 4 fractions
7	Squamous cell carcinoma RLL	T2N2M0	63 Gy, 35 fractions
8	Adenocarcinoma RUL	T1N1M0, recurrent	63 Gy, 30 fractions
9	NSCLC RUL	T1N2M1	60 Gy, 30 fractions
10	Squamous mid esophagus	T3N1M0	50.4 Gy, 28 fractions

$\mathrm{N}\mathrm{S}\mathrm{C}\mathrm{L}\mathrm{C}=\mathrm{n}\mathrm{o}\mathrm{n}‐\mathrm{s}\mathrm{m}\mathrm{a}\mathrm{l}\mathrm{l}‐\mathrm{c}\mathrm{e}\mathrm{l}\mathrm{l}\hspace{0.17em}\mathrm{l}\mathrm{u}\mathrm{n}\mathrm{g}\hspace{0.17em}\mathrm{c}\mathrm{a}\mathrm{n}\mathrm{c}\mathrm{e}\mathrm{r};$; $\mathrm{R}\mathrm{L}\mathrm{L}=\mathrm{r}\mathrm{i}\mathrm{g}\mathrm{h}\mathrm{t}\hspace{0.17em}\mathrm{l}\mathrm{o}\mathrm{w}\mathrm{e}\mathrm{r}\hspace{0.17em}\mathrm{l}\mathrm{o}\mathrm{b}\mathrm{e};$; $\mathrm{R}\mathrm{U}\mathrm{L}=\mathrm{r}\mathrm{i}\mathrm{g}\mathrm{h}\mathrm{t}\hspace{0.17em}\mathrm{u}\mathrm{p}\mathrm{p}\mathrm{e}\mathrm{r}\hspace{0.17em}\mathrm{l}\mathrm{o}\mathrm{b}\mathrm{e};$; $\mathrm{L}\mathrm{U}\mathrm{L}=\mathrm{l}\mathrm{e}\mathrm{f}\mathrm{t}\hspace{0.17em}\mathrm{u}\mathrm{p}\mathrm{p}\mathrm{e}\mathrm{r}\hspace{0.17em}\mathrm{l}\mathrm{o}\mathrm{b}\mathrm{e}$.